ArticleScientific reports2017
Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prognostic impact of para-aortic lymph node metastases in non-pancreatic periampullary cancer.World journal of surgical oncology · 2020Pooled it
- Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospective Study.Annals of gastroenterological surgery · 2026Article
- The Prognostic Role of Para-Aortic Lymph Node Metastasis in Patients with Resected Pancreatic Adenocarcinoma.Cancers · 2025Article
- Clinical significance of para-aortic lymph node metastasis for prognosis in patients with pancreaticobiliary cancer who underwent radical surgical resections.Turkish journal of surgery · 2025Article
- Prognostic Impact of Para-Aortic Lymph Node Metastasis in Resected Non-Pancreatic Periampullary Cancers.Annals of surgical oncology · 2024Article
- Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.European journal of radiology open · 2024Article
- Pancreaticoduodenectomy with Para-aortic Lymph Node Dissection for Periampullary Cancer.Indian journal of surgical oncology · 2024Article
- Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma.BMC surgery · 2023Article
- Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma.World journal of gastrointestinal surgery · 2022Article
- Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approachesAnnals of hepato-biliary-pancreatic surgery · 2022Article
- Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?Journal of gastrointestinal oncology · 2021Review
- Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.Langenbeck's archives of surgery · 2021Article
- The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No international consensus regarding the resection of the para-aortic lymph node (PALN) station Ln16b1 during pancreatoduodenectomy for pancreatic ductal adenocarcinoma (PDAC) has been reached. The present retrospectively investigated 264 patients with PDAC who underwent curative pancreatoduodenectomy or total pancreatectomy between 2005-2015. In 95 cases, the PALN were separately labelled and histopathologically analysed. Metastatic PALN (PALN+) were found in 14.7% (14/95). PALN+ stage was associated with increased regional lymph node metastasis. The median overall survival (OS) of patients with metastatic PALN and with non-metastatic PALN (PALN-) was 14.1 and 20.2 months, respectively. Five of the PALN+ patients (36%) survived >19 months. The OS of PALN+ and those staged pN1 PALN- was not significantly different (P = 0.743). Patients who underwent surgical exploration or palliative surgery (n = 194) had a lower median survival of 8.8 (95% confidence interval: 7.3-10.1) months. PALN status could not be reliably predicted by preoperative computed tomography. We concluded that the survival data of PALN+ cases is comparable with advanced pN+ stages; one-third of the patients may expect longer survival after radical resection. Therefore, routine refusal of curative resection in the case of PALN metastasis is not indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.